11 results about "Antigenic stimulation" patented technology

This invention provides a chimeric antigen receptor comprising an NFIX-encoding gene, a self-cleaving peptide sequence F2A, and a CAR-encoding sequence. The NFIX-encoding gene is located upstream and is linked to the CAR-encoding sequence via the self-cleaving peptide sequence F2A. The sequence of the NFIX-encoding gene is shown in SEQ ID NO. 01, and the sequence of the self-cleaving peptide sequence F2A is shown in SEQ ID NO. 03. This invention also provides a chimeric antigen receptor T cell expressing the aforementioned chimeric antigen receptor. This invention further provides the application of the aforementioned chimeric antigen receptor or the aforementioned chimeric antigen receptor T cell in the preparation of drugs for treating cancer. This invention improves the antitumor therapeutic effect of CAR-T cells by introducing the NFIX expression element into engineered T cells, thereby enhancing their functional stability, proliferative capacity, and cytotoxic activity under continuous antigen stimulation.

The invention relates to a method for predicting the evolution of an immune response in a subject towards an effector or suppressor response, based on cellular plasticity determined by the cytokine milieu generated after antigenic stimulation. The invention also allows for evaluating the generation of antigen-specific memory regulatory T cells in the evolution of the immune response. The invention also relates to a kit for carrying out the method according to the invention.

Compositions for the treatment of cancer that include CAR T cells in which expression of FOXO3 expression is silenced are disclosed in various aspects. In various other aspects, methods for preventing or delaying a development of dysfunction in a CAR T cell associated with chronic antigen stimulation are described that include silencing the expression of FOXO3 by the CAR T cell.

The present disclosure provides inducible constructs comprising transcription initiation and / or transcriptional regulatory elements. These constructs can be used to drive gene expression in response to specific cellular conditions (e.g., in the context of antigenic stimulation). In some embodiments, the constructs are incorporated as part of regulatory circuits useful for controlling the expression and regulation of cells expressing the engineered receptor.

The invention provides a drug-loaded group B neisseria meningitidis and a preparation method and application of a vaccine thereof. The preparation method comprises the following steps: (1) co-incubating attenuated group B neisseria meningitidis by using sulfonated NHS-biotin to obtain biotinylated attenuated group B neisseria meningitidis; (2) after the Pam3CSK4 and the MDP are respectively coupled with the BSA (bovine serum albumin), the Pam3CSK4 and the MDP are respectively coupled with the streptavidin, so that a Pam3CSK4-BSA-streptavidin conjugate and an MDP-BSA-streptavidin conjugate are obtained; and (3) carrying out mixed incubation on the biotinylated attenuated group B neisseria meningitidis, the Pam3CSK4-BSA-streptavidin conjugate and the MDP-streptavidin conjugate, so as to obtain the drug-loaded group B neisseria meningitidis. According to the invention, a remarkable synergistic interaction effect is generated in the aspect of an antigen stimulation effect, the defect of weak immunogenicity of attenuated group B neisseria meningitidis is overcome, and the application prospect is relatively good.

The invention relates to an IgG4 antibody specifically combined with dermatophagoides pteronyssinus extract and a preparation method thereof. The screening method comprises the following steps: 1) stimulating a lymph node organ with an antigen; 2) analyzing the stimulated lymph node organoid by combining single cell sequencing and an immune repertoire, and screening a potential IgG4 sequence; (3) preparing the potential IgG4 sequence into potential antibody protein in an in-vitro expression manner; and 4) respectively carrying out ELISA detection and biological layer interference technology verification on the potential antibody protein, wherein the antibody which can be specifically combined with the antigen is the IgG4 antibody. An antigen binding fragment of the obtained IgG4 antibody is formed by connecting a heavy chain fragment and a light chain through a disulfide bond, the nucleotide sequence of the heavy chain fragment is shown as any one of SEQ ID No: 1 to SEQ ID No: 3, and the nucleotide sequence of the light chain is shown as any one of SEQ ID No: 4 to SEQ ID No: 6.

The invention discloses application of a taste sense 2 receptor member 31 (TAS2R31) as a knockout target in cellular immunotherapy, and belongs to the technical field of biological medicines. Specifically, it is found for the first time that the proliferation capacity of tumor infiltrating lymphocytes (TIL cells) obtained after TAS2R31 gene is knocked out is remarkably improved, the killing capacity is remarkably enhanced, and the cell phenotype can be converted towards the direction more beneficial to anti-tumor immunity; meanwhile, the TIL cells with the TAS2R31 gene knocked out can release functional cell factors after being stimulated by antigens, and the TIL cells have definite anti-tumor immunocompetence. Therefore, the TAS2R31 is used as a new knockout target and is used for developing a new tumor treatment scheme based on TIL cells or TCR-T cells. The cell therapy provided by the invention provides a new strategy direction for tumor treatment by improving the multiplication capacity and the immune function of the TIL cells and the TCR-T cells.

This invention provides an ELISpot kit for detecting T-cell immunity in porcine epidemic diarrhea (PEDD) and its applications, belonging to the field of in vitro diagnostic technology. The hybridoma cell line 6E8-5G5, which secretes anti-porcine interferon-gamma monoclonal antibodies, can be used to prepare high-purity anti-porcine interferon-gamma monoclonal antibodies stably and in large quantities over a long period. Furthermore, an enzyme-linked immunospot (ELISpot) method based on PEDV N protein-specific IFN-γ is established. By detecting the level of specific T-cell immune responses against PEDV N protein after antigen stimulation, this provides technical support for the assessment of cellular immunity after PEDV infection or vaccine immunization.

The application belongs to the technical field of tumor immunotherapy, and particularly relates to an anti-mesothelin antibody and application thereof, and the application finds three mouse-derived antibodies with high affinity, and the antibodies are subjected to humanization treatment; the affinity is significantly higher than that of SS1 antibody. On this basis, a second-generation CAR-T cell based on the above antibody is constructed, and the in-vitro killing effect is better than that of a conventional SS1 CAR-T, and the CAR-T cell in a humanized form has tumor cell killing capacity equivalent to that of a mouse-derived CAR-T cell, and the cell exhaustion level is significantly reduced within a long time of 0-14 days after being stimulated by an antigen. The chimeric antigen receptor T cell has strong killing activity on mesothelin-positive tumor cells, uses a fully human antibody as an scfv, has no immunogenicity, can be repeatedly administered, and enhances the treatment effect of the CAR-T cell.

The invention provides a method for enriching tumor specific cells, and particularly relates to a method for obtaining tumor specific cells aiming at specific tumor species by enriching specific markers. The invention also provides application of the tumor specific cell. The separated immune cells have strong release ability to specific cytokines of lung tumors and cervical tumors, have strong specific killing ability to advanced tumors, or have high expression level of tumor specific recognition markers in a corresponding time window after tumor antigen stimulation. The sorting step reduces the amount of cells required for cell therapy or the in vitro culture time required for cell therapy.